Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Mitomycin C in High-Risk Colorectal Cancer
NCT04370925Phase 3Recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Jun 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c in colorectal cancer (CRC) (2 arms), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: Peritoneal recurrence-free survival at 3 years. Started Jun 2020; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04370925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370925.